IL-35: A potential target for the treatment of atherosclerosis

Pharmazie

Volumn 68, Issue 10, 2013, Pages 793-795

  Huang, Ying ^a   Lin, Ying Zhong ^a   Shi, Ying ^a   Ji, Qing Wei ^a  

^a PEOPLE'S HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 27; INTERLEUKIN 35; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ATHEROGENESIS; ATHEROSCLEROSIS; CELL MATURATION; CYTOKINE RELEASE; HUMAN; INFLAMMATION; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL;

ANIMALS; ATHEROSCLEROSIS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; HUMANS; INFLAMMATION; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P35;

EID: 84885436263     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.2928     Document Type: Review

References (33)

1. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z (2006) Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12: 178-180. (Pubitemid 43214743)
2. Alam SE, Nasser SS, Fernainy KE, Habib AA, Badr KF (2004) Cytokine imbalance in acute coronary syndrome. Curr Opin Pharmacol 4: 166-170. (Pubitemid 38444052)
3. Allan SE, Song-Zhao GX, Abraham T, McMurchy AN, Levings MK (2008) Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3. Eur J Immunol 38: 3282-3289.
4. Bardel E, Larousserie F, Charlot-Rabiega P, Coulomb-L'Herminé A, Devergne O (2008) Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol 181: 6898-6905.
5. Bettini M, Castellaw AH, Lennon GP, Burton AR, Vignali DA (2012) Prevention of Autoimmune Diabetes by Ectopic Pancreatic β-Cell Expression of Interleukin-35. Diabetes 61: 1519-1526.
6. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA (2011) Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 186: 6661-6666.
7. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450: 566-569. (Pubitemid 350190247)
8. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA, Rehg JE, Jones ML, Ni HT, Artis D, Turk MJ, Vignali DA (2010) IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 11: 1093-1101.
9. Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, Murray PJ, Vignali DA (2012). The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 13: 290-299.
10. de Boer OJ, Teeling P, Idu MM, Becker AE, van der Wal AC (2006). Epstein Barr virus specific T-cells generated from unstable human atherosclerotic lesions: implications for plaque inflammation. Atherosclerosis 184: 322-329. (Pubitemid 43049716)
11. Devergne O, Hummel M, Koeppen H, Le Beau MM, Nathanson EC, Kieff E, Birkenbach M (1996). A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 70: 1143-1145.
12. Devergne O, Birkenbach M, Kieff E (1997). Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A 94: 12041-12046. (Pubitemid 27467839)
13. Eid RE, Rao DA, Zhou J, Lo SF, Ranjbaran H, Gallo A, Sokol SI, Pfau S, Pober JS, Tellides G (2009) Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 119: 1424-1432.
14. Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK (1999) Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145: 33-43. (Pubitemid 29292698)
15. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A (1995) The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nature Med 1: 74-79.
16. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, Zeiher AM; CAPTURE Study Investigators (2003) Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 107: 2109-2114. (Pubitemid 36532192)
17. Jafarzadeh A, Nemati M, Rezayati MT (2011) Serum levels of interleukin (IL)-27 in patients with ischemic heart disease Cytokine 56:153-156.
18. Jankowski M, Kopiński P, Goc A (2010) Interleukin-27: biological properties and clinical application. Arch Immunol Ther Exp (Warsz) 58: 417-425.
19. Ji QW, Guo M, Zheng JS, Mao XB, Peng YD, Li SN, Liang ZS, Dai ZY, Mao Y, Zeng QT (2009) Downregulation of T helper cell type 3 in patients with acute coronary syndrome. Arch Med Res 40: 285-293.
20. Kempe S, Heinz P, Kokai E, Devergne O, Marx N, Wirth T (2009) Epsteinbarr virus-induced gene-3 is expressed in human atheroma plaques. Am J Pathol 175: 440-447.
21. Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW (2010) IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 184: 7144-7153.
22. Li X, Mai J, Virtue A, Yin Y, Gong R, Sha X, Gutchigian S, Frisch A, Hodge I, Jiang X, Wang H, Yang XF (2012) IL-35 is a novel responsive anti-inflammatory cytokine - a new system of categorizing anti-inflammatory cytokines. PLoS One 7: e33628.
23. Lin Y, Huang Y, Lu Z, Luo C, Shi Y, Zeng Q, Cao Y, Liu L, Wang X, Ji Q (2012) Decreased plasma IL-35 levels are related to the left ventricular ejection fraction in coronary artery diseases. PLoS ONE 7(12): e52490.
24. Liu JQ, Liu Z, Zhang X, Shi Y, Talebian F, Carl JW Jr, Yu C, Shi FD, Whitacre CC, Trgovcich J, Bai XF (2012) Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis. J Immunol 188: 3099-3106.
25. Loppnow H, Werdan K, Buerke M (2008) Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms. Innate Immun 14: 63-87.
26. Mor A, Luboshits G, Planer D, Keren G, George J (2006) Altered status of CD4+CD25+ regulatory T cells in patients with acute coronary syndromes. Eur Heart J 27: 2530-2537. (Pubitemid 44627295)
27. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, Liew FY (2007) IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37: 3021-3029. (Pubitemid 350131282)
28. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126.
29. Seyerl M, Kirchberger S, Majdic O, Seipelt J, Jindra C, Schrauf C, Stöckl J (2010) Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC. Eur J Immunol 40: 321-329.
30. Tedgui A, Mallat Z (2006) Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86: 515-581.
31. Uyemura K, Demer LL, Castle SC, Jullien D, Berliner JA, Gately MK, Warrier RR, Pham N, Fogelman AM, Modlin RL (1996) Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 97: 2130-2138. (Pubitemid 26143968)
32. Yang J, Yang M, Htut TM, Ouyang X, Hanidu A, Li X, Sellati R, Jiang H, Zhang S, Li H, Zhao J, Ting AT, Mayer L, Unkeless JC, Labadia ME, Hodge M, Li J, Xiong H (2008). Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and RORgamma t. Eur J Immunol 38: 1204-1214.
33. Zhong Y, Wang X, Ji Q, Mao X, Tang H, Yi G, Meng K, Yang X, Zeng Q (2012) CD4+LAP + and CD4 +CD25 +Foxp3 + regulatory T cells induced by nasal oxidized low-density lipoprotein suppress effector T cells response and attenuate atherosclerosis in ApoE(-/-) Mice. J Clin Immunol 32: 1104-1117.